Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy
European Heart Journal - Cardiovascular Pharmacotherapy · 2024
DOI: 10.1093/ehjcvp/pvae017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Morten Würtz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus, Denmark. Hauptthemen laut MEDLINE: Hemorrhage, Aspirin, Platelet Aggregation Inhibitors, Factor Xa Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Bayer AG.
Abstract (Originalsprache)
Aims
Guidelines recommend extended dual pathway inhibition (DPI) with aspirin and rivaroxaban in patients with chronic coronary syndrome (CCS) at high ischaemic risk. The CHADS-P2A2RC score improves risk prediction and enables antithrombotic treatment allocation in these patients. This study evaluated the net clinical benefit of DPI treatment according to baseline risk as classified by the CHADS-P2A2RC score in patients with CCS included in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial. Methods and results COMPASS patients with CCS (n = 14 670), randomized to aspirin alone or DPI, were stratified according to cardiovascular risk using the CHADS-P2A2RC score. Endpoints were major adverse cardiovascular events (MACE), all-cause death, fatal/critical organ bleeding, and composite adverse events (MACE and bleeding). Net clinical benefit was the 30-month risk difference of MACE and bleeding. Thirty-month incidences of MACE [7.9% vs. 3.9%, hazard ratio (HR) 2.01, 95% confidence interval (CI) 1.83–2.18] and fatal/critical organ bleeding (1.2% vs. 0.8%, HR 1.49, 95% CI 1.06–1.92) were higher in high-risk (CHADS-P2A2RC ≥ 4) than in low/moderate-risk (CHADS-P2A2RC < 4) patients. DPI reduced MACE (low/moderate risk: HR 0.62, 95% CI 0.47–0.82; high risk: HR 0.82, 95% CI 0.68–0.99, P for interaction 0.09) and all-cause death (low/moderate risk: HR 0.65, 95% CI 0.46–0.91; high risk: HR 0.81, 95% CI 0.65–1.00, P for interaction 0.29), without substantially increasing fatal/critical organ bleeding (low/moderate risk: HR 1.35, 95% CI 0.72–2.53; high risk: HR 1.18, 95% CI 0.73–1.90, P for interaction 0.73). DPI provided net clinical benefit of similar magnitude in low/moderate-risk (−1.81%, 95% CI −3.00 to −0.62) and high-risk (−1.96%, 95% CI −3.60 to −0.33) CCS patients.
Conclusion
As classified by the CHADS-P2A2RC score, low/moderate- and high-risk patients with CCS derived similar net clinical benefit and reduction in all-cause death from DPI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus, Denmark.
- Department of Cardiology, Regional Hospital Gødstrup, Hospitalsparken 15, DK-7400, Herning, Denmark.
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA.
- Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, L8L 2X2 Ontario, Canada.
- Research & Development, Bayer AG Pharmaceuticals, 42117 Wuppertal, Germany.
- Department of Clinical Medicine, Faculty of Health, Aarhus University, DK-8200, Aarhus, Denmark.
ORCID-Profile: Morten Würtz, Kevin Kris Warnakula Olesen, Deepak L Bhatt
Förderung
- Bayer AG
Zitieren
APA
Würtz, M., Olesen, K. K. W., Bhatt, D. L., Yusuf, S., Muehlhofer, E., Eikelboom, J. W., & Maeng, M. (2024). Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae017
Vancouver
Würtz M, Olesen KKW, Bhatt DL, Yusuf S, Muehlhofer E, Eikelboom JW, et al. Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae017
BibTeX
@article{Wrtz2024,
author = {Würtz, Morten and Olesen, Kevin Kris Warnakula and Bhatt, Deepak L and Yusuf, Salim and Muehlhofer, Eva and Eikelboom, John W and Maeng, Michael},
title = {Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2024},
doi = {10.1093/ehjcvp/pvae017}
}
EUVIMED